The ADCK5 Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ADCK5 gene, which encodes a mitochondrial protein kinase essential for coenzyme Q (CoQ) biosynthesis. This polyclonal knockout model offers a heterogeneous loss-of-function system derived through CRISPR/Cas9-mediated gene disruption, enabling researchers to study the collective impact of ADCK5 ablation within a pool of edited HeLa cells without clonal selection. Suitable for investigating mitochondrial disorders and metabolic dysfunction, this reagent serves as a versatile tool for functional genomics, drug screening, and pathway dissection in human cancer and metabolic research contexts.
HeLa cells, a human cervical adenocarcinoma cell line, are among the most widely used immortalized cell lines in biomedical research due to their robust growth, ease of transfection, and extensive characterization. Originating from a cervical cancer biopsy, HeLa cells retain epithelial properties and active metabolism, making them an appropriate host for studying mitochondrial function and coenzyme Q biology. Their high proliferation rate and well-documented genetic background facilitate reproducible assays, including metabolic flux analysis and gene expression profiling, providing a consistent platform for evaluating the consequences of ADCK5 disruption.
ADCK5 phosphorylates proteins within the coenzyme Q biosynthesis complex, stabilizing COQ3 and COQ5, thereby facilitating electron transport through mitochondrial respiratory chain supercomplexes. Upstream signals via PPARGC1A and metabolic stress regulate its activity. Downstream, ADCK5 promotes proper assembly of the COQ complex (including COQ2, COQ4, COQ6, COQ7, COQ9, ADCK3, and ADCK4), ensuring adequate CoQ production. Its disruption impairs respiratory chain activity and ATP synthesis, while increasing oxidative stress.
In HeLa cells, ADCK5 knockout provides a significant model for dissecting the molecular basis of primary coenzyme Q10 deficiency and associated mitochondrial encephalopathies or ataxias. Given the cancer cell context, ADCK5 loss may also impair metabolic adaptability, sensitizing cells to energetic stress and apoptosis. This model enables the study of how CoQ deficiency intersects with cancer cell metabolism, mitochondrial quality control, and redox homeostasis, offering insights into therapeutic vulnerabilities in tumors reliant on oxidative phosphorylation.
Typical applications include mitochondrial disease modeling, coenzyme Q deficiency studies, metabolic research, and drug screening. Compatible assays include Western blotting, Seahorse-based respiration analysis, Coenzyme Q HPLC quantification, RT-qPCR, and apoptosis assays. This product enables detailed exploration of ADCK5 biology and mitochondrial pathophysiology. For further information, please contact Ascent Research.
